A phase 1/2 trial of Photodynamic Therapy (PDT) in prostate cancer, run by SpectraCure AB, now recruiting.
Photodynamic Therapy of Primary Localized Prostate Cancer With the SpectraCure P18 System is a phase 1/2 interventional study registered as NCT06807359 by SpectraCure AB, with 43 participants planned, started 2025-01-06 and due to reach its primary completion in 2028-01. Interventions recorded: Photodynamic Therapy (PDT) and Verteporfin Injection.
Shares SpectraCure, Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.